How would you approach therapy for a patient with a history of classical HL who achieved a CR to 6 cycles of Brentuximab plus AVD who now presents with widespread non-GC DLBCL?

Depending on the time from initial treatment, age, and the patient's fitness, could consider several options.

1. If it has been within a short interval, then would be concerned that the DLBCL was present during or shortly after exposure to anthracycline. In that case, would treat with R-CEOP with consideration of referral for consolidative autologous stem cell transplant if the patient is eligible. Data is lacking to justify transplant in this situation but would approach similar to tDLBCL and ass...

Since ABVD consists of anthracycline, alkylator, and vinca alkaloid, R-CHOP is unlikely to result in durable remission. I would use a rituximab-containing regimen such as RICE or R-GEMOX and proceed with autologous stem cell transplant.